Chimaeric antigen receptor T-cell therapy for tumour immunotherapy

Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28.

Abstract

Chimaeric antigen receptor (CAR) T-cell therapies, as one of the cancer immunotherapies, have heralded a new era of treating cancer. The accumulating data, especially about CAR-modified T cells against CD19 support that CAR T-cell therapy is a highly effective immune therapy for B-cell malignancies. Apart from CD19, there have been many trials of CAR T cells directed other tumour specific or associated antigens (TSAs/TAAs) in haematologic malignancies and solid tumours. This review will briefly summarize basic CAR structure, parts of reported TSAs/TAAs, results of the clinical trials of CAR T-cell therapies as well as two life-threatening side effects. Experiments in vivo or in vitro, ongoing clinical trials and the outlook for CAR T-cell therapies also be included. Our future efforts will focus on identification of more viable cancer targets and more strategies to make CAR T-cell therapy safer.

Keywords: T cells; chimeric antigen receptor; immunotherapy; tumor specific or associated antigens.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer / adverse effects
  • Adoptive Transfer / methods
  • Animals
  • Antigens, Neoplasm / immunology
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Neoplasms / blood supply
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / immunology
  • Neovascularization, Pathologic / therapy
  • Protein Conformation
  • Receptors, Antigen, T-Cell / chemistry
  • Receptors, Antigen, T-Cell / immunology
  • Receptors, Antigen, T-Cell / therapeutic use*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation

Substances

  • Antigens, Neoplasm
  • CD19-specific chimeric antigen receptor
  • Receptors, Antigen, T-Cell